Aclaris Therapeutics (ACRS) Shares Outstanding (2014 - 2026)

Aclaris Therapeutics' Shares Outstanding (Entity) history runs 13 years deep, the most recent figure standing at $139.7 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Entity) rose 28.99% year-over-year to $139.7 million; the TTM figure through Mar 2026 stood at $139.7 million (up 28.99% YoY), while the FY2025 annual figure was $120.5 million, up 55.89% from the prior year.
• Shares Outstanding (Entity) for Q1 2026 stood at $139.7 million, up from $120.5 million in the prior quarter.
• The five-year high for Shares Outstanding (Entity) was $139.7 million in Q1 2026, with the low at $61.7 million in Q1 2022.
• The 5-year median for Shares Outstanding (Entity) is $71.2 million (2024), against an average of $83.4 million.
• The sharpest annual moves came in 2024 and 2025: Shares Outstanding (Entity) increased 0.8% in 2024, then soared 55.89% in 2025.
• Aclaris Therapeutics' Shares Outstanding (Entity) stood at $66.7 million in 2022, then increased by 6.31% to $70.9 million in 2023, then climbed by 9.03% to $77.3 million in 2024, then jumped by 55.89% to $120.5 million in 2025, then advanced by 15.9% to $139.7 million in 2026.
• Business Quant data shows ACRS's Shares Outstanding (Entity) at $139.7 million in Q1 2026, $120.5 million in Q4 2025, and $108.3 million in Q3 2025.